Long-term safety and efficacy of bisphosphonate therapy in advanced lung cancer with bone metastasis.
Zixin WeiBo PanDexin JiaYan YuPublished in: Future oncology (London, England) (2022)
Aim: This retrospective, observational study evaluated the long-term (>12 months) safety and effectiveness of bisphosphonate. Methods: Data collected for 359 patients included quantity and proportion of adverse events (AEs) and skeletal-related events (SREs), and times to first AE and first SRE. Results: Patients in the ≤24-month group experienced significantly fewer AEs compared with the >24-month treatment group (p = 0.008), and treatment for >24 months was a potential risk factor for AEs (p = 0.05). Neither the proportion nor the risk of SRE was significantly associated with therapy duration (p = 0.525 and 0.084, respectively). Conclusion: Bisphosphonate treatment beyond 2 years may increase the risk of AEs, but may prolong SRE-free survival early after 24 months, compared with medication administered for ≤24 months.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- free survival
- peritoneal dialysis
- systematic review
- stem cells
- machine learning
- bone marrow
- combination therapy
- patient reported outcomes
- bone mineral density
- electronic health record
- patient reported
- postmenopausal women
- replacement therapy
- data analysis
- bone loss